androgen receptor pathway inhibitors

Tailoring Systemic Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Evidence by Disease Volume and Timing of Metastasis

By MedXY 12/17/2025

A living network meta-analysis refines treatment strategies for mHSPC subgroups, favoring triplet therapy in synchronous high-volume cases and ARPI doublet therapy in others.

news Oncology Urology

Evolving Treatment Patterns and Survival Outcomes in Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

A retrospective study in US veterans reveals increased use of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), showing improved survival over ADT alone. ARPIs and docetaxel demonstrate comparable overall survival, with ARPIs providing longer progression-free survival.

news Oncology Urology

Age-Dependent Benefits of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Meta-Analysis

By MedXY 10/30/2025

This meta-analysis reveals that systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, with greater benefits in younger men and nuanced effects in older men, especially based on disease volume.

news Oncology Urology

Age-Related Impact of Treatment Intensification on Survival in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

Systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, but its benefit varies by age and disease volume. Older men, particularly with low-volume disease, may have limited survival gains from intensified therapy.